Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Chylek who wrote (305)	6/1/1999 7:15:00 PM
From: Walter Morton	Read Replies (1) of 2742

These are some of the reasons I think CIST is worth more than $1: "Anti-IL-1ß antibodies can neutralize the effects of IL-1ß mediated nitric oxide and PGE2 production in bovine chondrocytes and human OA-affected cartilage. One pg of anti-IL-1ß antibody can neutralize effects of approximately 1 ng/ml of IL-1ß in cell based assays and human organ cultures. This neutralizing antibody has enormous potential to attenuate the effects of IL-1ß in various diseases driven by excess amount of IL-1ß." "In December 1995, a U.S. patent related to the Company's assay was issued. In addition to the issued IL-1 patents, a number of applications of the Institutions and Cistron are pending in the U.S. and foreign countries covering an inhibitor to IL-1, certain IL-1 uses, IL-1 Antibodies, and additional claims for the IL-1 Assay." "Addition of IC8 monoclonal to the IL-1 bioassay resulted in a loss of signal (see figure). IC8 neutralized biological activity of human IL-1b." "We conclude that Cistron's anti-human IL-1b monoclonal antibody is highly effective in blocking the effect of IL-1b in whole animals. The antibody may be useful in therapy of IL-1 mediated diseases." "Cistron's 1C8 mouse monoclonal was able to significantly reduce the production of IL-6 by blocking the activity of IL-1b from the patient's plasma cells." "Using 1m g/mL of Cistron's 1C8 mouse monoclonal to block IL-1b activity, a significant decrease was seen in the production of nitric oxide (49% and 46% reduction, respectively) in samples." "Anti-IL-1ß antibodies can neutralize the effects of IL-1ß mediated nitric oxide and PGE2 production in bovine chondrocytes and human OA-affected cartilage. One pg of anti-IL-1ß antibody can neutralize effects of approximately 1 ng/ml of IL-1ß in cell based assays and human organ cultures. This neutralizing antibody has enormous potential to attenuate the effects of IL-1ß in various diseases driven by excess amount of IL-1ß." "observations suggest that treatment of patients with an effective IL-1ß inhibitor (i.e. an humanized anti-IL-1ß antibody) may be a rational therapeutic approach in individuals with early myeloma or high-risk MGUS." "Based upon a recent publication in Arthritis and Rheumatism [1998 Dec;41(12)2196-204] the Company believes their antibody patent on interleuken-1b (Il-1b ) presents a major opportunity in rheumatoid arthritis." "In a recently published 24 week, double-blind, randomized, placebo-controlled study by Amgen on the Il-1b receptor antagonist resulted in a significant clinical benefit that was observed with the rate of radiological progression being significantly reduced. There were no serious adverse events and this was the first biologic agent to demonstrate a beneficial effect on the rate of joint erosion in rheumatoid arthritis." emedtrade.com emedtrade.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next